Wells Fargo & Company Gilead Sciences, Inc. Call Options Transaction History

Wells Fargo & Company

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $3.54 Million - $4.43 Million	-61,100 Reduced 37.93%	100,000 $5.95 Million
Q4 2020 Feb 09, 2021	SELL	$56.65 - $64.55 $7.87 Million - $8.97 Million	-138,900 Reduced 46.3%	161,100 $111,000
Q3 2020 Nov 05, 2020	BUY	$62.1 - $78.08 $12.3 Million - $15.5 Million	198,800 Added 196.44%	300,000 $30,000
Q1 2020 May 14, 2020	BUY	$62.63 - $80.22 $6.34 Million - $8.12 Million	101,200 New	101,200 $507,000

1,926

993M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.